US SEC Filings Daily Market Digest — March 24, 2026

24-03-2026

Curbline Properties Corp.'s 2026 DEF 14A proxy statement details its board committee structures, with the Compensation Committee holding 4 meetings in 2025 and all members independent, and the Nominating and Sustainability Committee also holding 4 meetings. Non-employee directors received total cash compensation ranging from $75,000 to $207,500 in 2025 with no stock awards recognized that year, while each held 8,632 unvested RSAs from 2024 grants valued at an initial $300,000 upfront. The proxy includes a Say-on-Pay proposal for advisory approval of named executive officer compensation, emphasizing alignment with performance, alongside stock ownership guidelines met by all directors ($375,000 minimum).

• ·Non-employee directors receive $2,000 per excess Board meeting fee ($3,000 for Chairman); $2,000 per excess committee meeting fee for non-chairs ($3,000 for chairs).
• ·All non-employee directors met $375,000 stock ownership guidelines as of Dec 31, 2025, ahead of October 15, 2029 deadline.
• ·Company maintains Insider Trading Policy with pre-clearance for directors/officers and quarterly blackouts; prohibits hedging/pledging for directors and VP-level+ officers.

24-03-2026

Achieve Life Sciences reported Q4 and FY 2025 financial results, with cash and equivalents at $36.4M (up 6% from $34.4M prior year), but operating expenses surged 21% YoY to $14.7M in Q4 (driven by G&A doubling to $10.9M) and 41% to $54.9M annually, resulting in net losses of $14.7M and $54.7M respectively (up 19% and 37% YoY). The company advanced cytisinicline development with FDA NDA acceptance (PDUFA June 20, 2026), ORCA-OL trial completion (334 participants), and a U.S. manufacturing partnership with Adare Pharma Solutions for potential H1 2027 launch, while noting FDA observations at one manufacturer. Additional progress includes ORCA-3 publication in JAMA Internal Medicine and selection for FDA Commissioner's National Priority Voucher for vaping cessation.

• ·FDA observations at one cytisinicline NDA manufacturer for solid oral dose manufacturing, with remedial action plan in communication.
• ·Technology transfer to Adare Pharma Solutions commenced for U.S. manufacturing.
• ·Completed third-party logistics and specialty pharmacy partner selection process.
• ·Convertible debt: current portion $3.7M (2025) vs $0 (2024); non-current $11.2M vs $9.8M.
• ·Total assets $41.8M (2025) vs $38.6M (2024).

24-03-2026

Concentrix reported first quarter fiscal 2026 revenue of $2,500.4 million, up 5.4% year-over-year as reported (1.9% on a constant currency basis), with strong momentum in iX Suite enterprise wins. However, profitability metrics declined significantly, including GAAP operating income down 29.8% to $118.6 million, non-GAAP operating income down 8.2% to $295.0 million, and adjusted EBITDA down 6.9% to $348.2 million. The company maintains its full-year fiscal 2026 outlook, projecting reported revenue of $10.035 billion to $10.180 billion (1.5% to 3.0% constant currency growth).

• ·Paid quarterly dividend of $0.36 per share on February 10, 2026; next dividend of $0.36 per share payable May 5, 2026 to shareholders of record April 24, 2026.
• ·Q2 FY2026 revenue guidance: $2.460B to $2.485B (1.0% to 2.0% constant currency growth).
• ·Q2 FY2026 non-GAAP diluted EPS guidance: $2.57 to $2.69.
• ·FY2026 non-GAAP operating income guidance: $1,240M to $1,290M.
• ·FY2026 non-GAAP diluted EPS guidance: $11.48 to $12.07.
• ·Effective tax rate expected at approximately 25% for Q2 and FY2026.
• ·Share repurchases at average cost of $40.06 per share in Q1 FY2026.

24-03-2026

Paysign, Inc. reported full-year 2025 revenues of $82.0 million, up 40.5% YoY from $58.38 million, driven by explosive 167.8% growth in pharma revenue to $33.89 million from 55 new patient affordability programs, though plasma revenue grew modestly 4.0% to $45.62 million despite adding 115 centers, offset by declining average donations per center and lower average monthly revenue per center. Net income increased 97.9% to $7.55 million with Adjusted EBITDA up 107.3% to $19.94 million; however, Q4 net income was essentially flat at $1.36 million (-0.8% YoY) and Q4 gross margin dipped slightly to 57.7% from 58.9%. The company exited 2025 with $21.07 million unrestricted cash, zero debt, and issued upbeat 2026 guidance for $106.5-110.5 million revenue (30-35% growth).

• ·Gross profit margin FY2025: 59.4% (up from 55.1% in 2024); Q4 2025: 57.7% (down from 58.9%).
• ·Operating margin FY2025: 9.0% (up from 1.7%); Q4 2025: 8.1% (up from 3.0%).
• ·2026 guidance: Revenue $106.5-110.5M (30-35% YoY growth), Adjusted EBITDA $30-33M, Net income $13-16M.
• ·Q1 2026 guidance: Revenue $27.0-27.5M (45.2-47.8% YoY), 137 patient programs and 589 plasma centers exiting quarter.

24-03-2026

Bright Mountain Media reported full-year 2025 revenue of $59.2 million, up 4% or $2.5 million YoY from $56.7 million, primarily driven by advertising technology growth, though partially offset by declines in media services. Q4 2025 revenue declined 8% to $15.7 million from $17.1 million amid industry challenges and cautious advertiser spending, with gross margin down 23% to $4.2 million. Net losses improved to $13.5 million for FY 2025 (down 21% YoY) and $3.3 million for Q4 (down 13% YoY), while Adjusted EBITDA rose 278% to $3.0 million for the year but fell to $1.1 million in Q4.

• ·FY 2025 segment revenues: advertising technology $21.7M, consumer insights $26.6M, creative services $8.5M, digital publishing $1.5M, media services $0.988M.
• ·Q4 2025 segment revenues: advertising technology $7.3M, consumer insights $5.9M, creative services $1.3M, digital publishing $0.26M, media services $0.967M.
• ·Cash and equivalents down to $1.4M from $2.5M at Dec 31, 2024; accounts receivable up to $16.3M from $15.0M.
• ·Current liabilities surged to $116.2M from $33.8M, driven by $84.3M current note payable (Centre Lane Senior Secured Credit Facility).
• ·Impairment of goodwill and intangibles: $786K in Q4 and FY 2025.

24-03-2026

Ernexa Therapeutics Inc., a preclinical-stage company developing synthetic allogeneic iMSC therapies including lead candidate ERNA-101 for platinum-resistant ovarian cancer (with IND submission planned for 2026 and Phase I trial in H2 2026), completed a public offering on February 10, 2026, raising net proceeds of approximately $9.5M through the sale of 19M shares and warrants at $0.50 combined and 2M pre-funded warrants at $0.49. This boosted stockholders’ equity from $2.4M at December 31, 2025, to exceed the Nasdaq $2.5M minimum. However, on March 18, 2026, the company received a Nasdaq notice for failing the $1.00 minimum bid price rule and is ineligible for the standard 180-day compliance period due to a prior 1-for-15 reverse stock split in June 2025, prompting a hearing request with delisting risk.

• ·Warrants from 2026 Offering exercisable at $0.68 per share, trading under ERNAW since February 6, 2026, expire on 5-year anniversary or 180 days post Phase 1 ERNA-101 data release.
• ·Pre-funded warrants exercisable at $0.01 per share, fully exercised by February 18, 2026.
• ·Series A Preferred Stock: 156,112 shares outstanding, $0.10 annual cumulative dividend per share, $1.00 liquidation preference, conversion rate of 75.9225 (approx. 0.0137 common shares per preferred share at Dec 31, 2024 post-split).
• ·1-for-15 reverse stock split effective June 10, 2025.

24-03-2026

Sylwia Nowak Hauman resigned as CFO of FOXO Technologies Inc. on March 18, 2026, citing concerns over internal controls, financial reporting processes, and finance team resourcing, which the Company disputes as unfounded while affirming improvements and commitment to timely 10-K filing. Celene Laurene Rattray Grant, age 44 and a returning consultant with prior Company experience, was appointed as the new CFO on March 24, 2026, bringing over 15 years in financial management focused on healthcare. Her compensation includes a $200,000 annual base salary and eligibility for up to $25,000 discretionary bonus.

• ·No family relationships between Ms. Grant and any director or executive officer.
• ·No transactions requiring disclosure under Item 404(a) of Regulation S-K.
• ·Ms. Grant is a CPA with BS in Accounting from Florida Atlantic University and MBA from Nova Southeastern University.
• ·Ms. Grant previously served as consultant Financial Controller for Company's predecessor (April 2018-June 2021) and returned as consultant (April 2024-November 2025).

24-03-2026

Artelo Biosciences filed an S-1 on March 24, 2026, to register resale of shares under a January 30, 2026 ELOC Purchase Agreement with Square Gate for up to $25M initial commitment (expandable to $50M), issuing $500K in commitment shares/warrants that cause dilution and potential stock price pressure. The company effected a 1-for-3 reverse stock split on March 10, 2026, reducing outstanding shares from 2.12M to 736K amid Nasdaq delisting risks, and issued a $237K 12% bridge note (for $210K net) on March 12, 2026; however, Nasdaq granted a compliance extension to March 30, 2026, for $2.5M minimum equity while reconvening its annual meeting on January 30, 2026, with only 50.4% quorum.

• ·ELOC puts limited to lesser of 100% 5-day avg daily volume, 30% daily volume, or $500K.
• ·Bridge note convertible at greater of $0.125 or 75% of lowest 10-day trading price upon default.
• ·Pre-funded warrants exercisable at $0.003 per share (cashless, no expiration).
• ·Nasdaq annual meeting deficiency cured via January 30, 2026 reconvened meeting.
• ·Prohibited from variable rate transactions during ELOC standstill periods.

24-03-2026

QXO, Inc. (QXO-PB) filed DEFA14A additional proxy materials on March 24, 2026, for its virtual annual stockholder meeting on May 5, 2026, at 10:00 AM EDT. Shareholders will vote on electing seven director nominees (Brad Jacobs, Jason Aiken, Marlene Colucci, Mario Harik, Mary Kissel, Jared Kushner, and Allison Landry), ratifying Deloitte & Touche LLP as independent auditors for fiscal year 2026, and an advisory vote approving executive compensation, with the board recommending FOR all items. Materials can be requested by April 21, 2026, via www.ProxyVote.com or other specified methods.

• ·Virtual meeting link: www.virtualshareholdermeeting.com/QXO2026
• ·Material request deadline: April 21, 2026
• ·Voting platform: www.ProxyVote.com with control number required for requests

24-03-2026

American Water Works Company, Inc. (AWK) filed its 2026 Proxy Statement ahead of its virtual annual meeting on May 13, 2026, highlighting its position as the largest U.S. water and wastewater utility serving 14 million people across 24 states with approximately 7,000 employees as of December 31, 2025, and plans for $3.7B in capital investments in 2026 for infrastructure and acquisitions. The filing discloses a merger agreement signed October 26, 2025, to acquire Essential Utilities, Inc. in a stock-for-stock transaction, with closing expected by end of Q1 2027 subject to regulatory approvals. It also includes executive compensation data via XBRL tags for 2021-2025 covering PEOs and NEOs such as Ms. Hardwick and Mr. Griffith.

• ·Annual meeting: May 13, 2026 at 10:00 a.m. ET, virtual at www.virtualshareholdermeeting.com/AWK2026
• ·Record date: March 17, 2026
• ·Merger closing estimate: end of Q1 2027, subject to regulatory approvals
• ·Core strategy areas: operations, capital, regulatory
• ·Core values: safety first, trust/dignity/respect, one team, environmental leadership, high performance

24-03-2026

Artificial Intelligence Technology Solutions, Inc. (AITX) filed an 8-K on March 24, 2026, furnishing a press release announcing that its RAD division is expanding its presence in Alaska through a new ROSA order, which highlights the product's reliable performance in extreme weather conditions. The press release is attached as Exhibit 99.1 under Item 8.01 Other Events. No financial metrics or period-over-period comparisons were disclosed.

• ·Filing includes Exhibit 99.1: Press release dated March 24, 2026.
• ·Company address: 10800 Galaxie Avenue, Ferndale, Michigan 48220.
• ·Registrant is not an emerging growth company.

24-03-2026

Vertical Aerospace Ltd. reported a net profit of £233M for the year ended December 31, 2025, swinging from a £781M loss in 2024, driven by a £330M net finance gain including £306M related party finance income. However, the operating loss widened 108% to £127M from £61M, with R&D expenses up 20% to £72M and administrative expenses up 23% to £53M, while cash used in operating activities nearly doubled to £83M from £46M. The filing raises substantial doubt on going concern due to limited cash, recurring operational losses, and dependency on additional capital.

• ·Basic EPS £2.63 for 2025 vs (£38.46) for 2024.
• ·Diluted EPS (£0.57) for 2025.
• ·Net cash from investing activities £2.6M in 2025 vs £1.7M in 2024.
• ·Income tax credit £30M in 2025 vs charge of £0.045M in 2024.
• ·Total comprehensive income £240M in 2025 vs loss of £757M in 2024.
• ·For 2023: Operating loss £102M, net loss £60M.

24-03-2026

FTC Solar, Inc. entered into a Second Amendment and Limited Waiver to its Credit Agreement on March 23, 2026, waiving a prior purchase order covenant breach for the quarter ended December 31, 2025, and reclassifying its $19.9M term loan balance from current to long-term debt (excluding scheduled repayments). However, the amendment requires principal repayments totaling $10M ($2.5M paid March 23, $2.5M due May 22, $5M due September 30, 2026) and imposes stringent new covenants, including minimum unrestricted cash of $15M by June 30, 2026 ($10M thereafter), quarterly revenue targets starting at $25M for June 2026 rising to $75M by December 2026, and consolidated EBITDA minimums of $10M for the 12 months ending December 31, 2026.

• ·Purchase order covenant waived for quarter ended December 31, 2025 and will not apply until quarter ending March 31, 2027.
• ·New covenants include direct tracker margin thresholds commencing March 31, 2026 and purchase order amounts thresholds from March 31, 2027.
• ·Failure to make ECF Repayment Amounts constitutes an event of default.

24-03-2026

CareTrust REIT reported exceptional 2025 performance, including 17% YoY Normalized FFO per share growth to $1.76, record $1.764B capital deployment, market capitalization surpassing $8.3B (up from $5.1B at end-2024), and disciplined year-end leverage of 0.89x net debt to normalized run-rate EBITDA. The proxy seeks approval for named executive officer compensation, with 88% of CEO target pay performance-based and at risk, annual incentives paying out at 300% of target, and enhancements from stockholder engagement addressing prior concerns like the 2024 special award. No material declines noted, with sustained TSR outperformance including top 10-year total return of 493% among U.S. healthcare REITs.

• ·Annual incentive payout at 300% of target: NFFO per share at High ($1.7602 vs target $1.7268), Capital Deployment at Super ($1.764B vs $1.5B), Leverage at High (0.89x vs 3.5x target).
• ·2025 Base LTI: CEO $4.8M total (50% PRSUs tied to 3-yr relative TSR, 85th percentile for max, absolute TSR cap); Outperformance Grant earned (CEO $3M PRSUs, re-earned on 3-yr TSR).
• ·Q2 2025 leverage peaked at 2.0x net debt to annualized normalized run-rate EBITDA before improving.
• ·10-year total return of 493%, top among U.S. healthcare REITs.

24-03-2026

Star Equity Holdings, Inc. filed a Form S-3 registration statement on March 24, 2026, establishing a shelf for up to $25M in securities including common stock, preferred stock, debt securities, and others to be offered from time to time. The filing also includes a resale prospectus allowing a selling stockholder to offer up to 1,014,056 shares of common stock and 787,217 shares of preferred stock acquired via merger and exchange transactions. The company qualifies as a smaller reporting company with $28.59M aggregate market value of non-affiliate common stock and is eligible to sell up to $9.53M under General Instruction I.B.6.

• ·Common stock last sale price $9.69 per share on March 23, 2026
• ·Preferred stock last sale price $10.07 per share on March 23, 2026
• ·Common stock highest closing price $11.24 per share on January 28, 2026
• ·Merger conversion: Star Operating common stock to 0.23 Star common shares; preferred stock 1:1 to Star Series A Preferred
• ·No prior sales under General Instruction I.B.6 in preceding 12 months

24-03-2026

News Corporation filed an 8-K on March 24, 2026, disclosing information provided to the Australian Securities Exchange (ASX) regarding its ongoing $1 billion stock repurchase program authorizing purchases of Class A (NWSA) and Class B (NWS) common stock. The filing attaches Exhibits 99.1 and 99.2 with the specific ASX disclosures but does not detail any new repurchase transactions in the body. Forward-looking statements note potential repurchases subject to market conditions and other factors.

24-03-2026

ReserveOne Holdings, Inc. filed a Form 425 disclosing communications made on March 23, 2026, via LinkedIn, X accounts, and an interview by Sebastian Bea at the DC Blockchain Summit 2026, promoting its strategic focus on long-term impacts of technologies like stablecoins in the context of its pending business combination with M3-Brigade Acquisition V Corp., originally agreed on July 7, 2025. The filing includes standard SEC disclaimers, a proxy statement/prospectus reference, and extensive risk factors highlighting uncertainties such as deal completion failure, high crypto volatility, regulatory risks, and potential high redemptions by M3-Brigade shareholders. No financial metrics or performance data were provided.

24-03-2026

Silver Bow Mining Corp. filed an S-1/A registration statement on March 23, 2026, disclosing mineral properties growing modestly to $38.3M as of Dec 31, 2025 from $37.3M in 2024 (+2.7%) following the $1.0M Goldsmith Block acquisition, while property and equipment net rose sharply to $253K (+154%) driven by additions and $36K depreciation expense (up 23% YoY). The company completed the Ferry Lane acquisition and related Lane F settlement for total consideration of $9.8M, including shares and cash payments, and raised approximately $6.6M through multiple small financings in 2024-2025. However, it remains in the exploration stage with ongoing environmental remediation reserves increasing slightly to $223K and annual property taxes around $13K-$17K.

• ·Lane F NSR Royalty of 2% on certain mineral properties, buyout option for $7.5M until Sep 19, 2034 (inflation-adjusted thereafter)
• ·Annual property tax payments approx. $13K (2025) to $17K (2024) to maintain mineral properties
• ·Multiple 2024-2025 financings raised funds ranging from $75K to $2.3M per tranche, primarily via units with warrants at $2.50-$6.00 exercise prices expiring 2026-2027

24-03-2026

Ocean Thermal Energy Corp (CPWR) reported its first annual revenue of $3.0M in 2025, up from $0 in 2024, with gross profit of $0.6M and improved operating loss of $0.2M versus $1.6M prior year. However, a massive $66.2M unfavorable change in fair value of derivative liability drove net loss to $69.3M from $1.2M, ballooning total liabilities to $114.9M from $44.6M and stockholders' deficit to $113.4M from $44.6M amid going concern warnings and defaulted debt. Cash improved to $0.4M from $16K, supported by financing inflows.

• ·Operating cash use improved to $93K from $563K YoY.
• ·Interest expense increased to $2.9M from $2.5M.
• ·Accounts receivable arose at $1.1M in 2025.
• ·Common stock subscribed $447,500 in 2025.
• ·Cash paid for interest: $353K in 2025 vs $64K in 2024.

24-03-2026

On March 23, 2026, lenders under Inotiv, Inc.'s Credit Agreement (dated November 5, 2021) granted a limited waiver for the minimum liquidity covenant specifically for the March 20, 2026, and March 27, 2026, test dates. No other provisions of the Credit Agreement were amended. This disclosure signals potential liquidity shortfalls but provides temporary compliance relief without broader changes.

• ·Credit Agreement originally dated November 5, 2021, among Inotiv, Inc., certain subsidiaries, and lenders party thereto.

24-03-2026

This S-4/A filing details the proposed mergers of Fundrise Merger Entities (Development eREIT, West Coast, East Coast, Growth eREIT II, and others) into Fundrise eREIT, LLC, with aligned investment objectives focused on current income and long-term capital appreciation through diversified real estate portfolios. Distribution policies involve quarterly payouts primarily from operations, but historically relied on non-cash sources like borrowings and asset sales, with total such amounts decreasing overall YoY from FY2024 to FY2025 across most entities (e.g., Development eREIT down 54%, Growth II down 75%), though West Coast saw a slight 8% increase. Fundrise eREIT aims to qualify as a REIT (90% distribution requirement) while maintaining Investment Company Act exemptions via limits like the 40% test and 80%+ real estate focus.

• ·No active or pending material litigation as of filing date.
• ·Fundrise eREIT holding period for redemptions post-merger will consider prior holdings in merger entities.
• ·Manager has discretion to amend policies without shareholder vote.

24-03-2026

Audax Private Credit Fund's investment portfolio expanded 46% to $949.8M at fair value as of December 31, 2025 from $651.0M at December 31, 2024, driven by $474.1M in new investments, with the number of portfolio investments rising to 116 from 43. Total investment income increased to $64.9M from $15.1M over the respective periods; however, weighted average yields declined to 8.28% from 10.07%, net unrealized losses of $5.8M were recorded versus $4.9M gains prior, and total expenses rose to $37.2M from $7.8M.

• ·Leverage facility committed increased to $600M from $500M; outstanding principal rose to $494.3M from $343.0M as of Dec 31 2025 vs 2024.
• ·Unitranche Debt at fair value: $589.1M (Dec 31 2025) vs $487.5M (Dec 31 2024); First Lien Debt: $295.1M vs $112.8M.
• ·Principal repayments: $166.5M (2025) vs $29.2M (2024 period).
• ·Commencement of operations: October 10, 2024.

24-03-2026

AMC Entertainment Holdings, Inc. filed an 8-K on March 24, 2026, covering Items 3.02 (Unregistered Sales of Equity Securities), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). The filing attaches Exhibit 5.1, an opinion from Weil, Gotshal & Manges LLP, and related consent in Exhibit 23.1. The report was signed by Edwin F. Gladbach, Senior Vice President, General Counsel and Secretary, on March 23, 2026.

• ·Items reported: 3.02, 8.01, 9.01
• ·Exhibits: 5.1 (Opinion of Weil, Gotshal & Manges LLP), 23.1 (Consent included in 5.1), 104 (Cover Page Interactive Data File)

24-03-2026

Cantor Fitzgerald Income Trust, Inc. reported a net loss of $13.5M for the year ended December 31, 2025, including an $8.4M loss attributable to common stockholders and a $4.8M impairment on real estate investments. Funds from Operations were positive at $10.3M and Modified Funds from Operations at $8.4M; however, total distributions declined 15% YoY to $17.9M from $21.1M in 2024, fully funded by operating cash flows of $27.4M. Net Asset Value was $284.4M, or approximately $20.10 per share across share classes, with debt obligations at $565M.

• ·Cash flows from investing activities: -$10.9M
• ·Cash flows from financing activities: -$29.4M
• ·Stockholders’ equity under U.S. GAAP: $470.3M (Dec 31, 2025)
• ·Investment in infrastructure fund at fair value: $8.7M (Dec 31, 2025)
• ·Real estate depreciation and amortization: $35.8M

24-03-2026

On March 19, 2026, Flowco Holdings Inc. entered into an underwriting agreement for the public offering of 7,800,000 shares of Class A common stock by certain selling stockholders at $22.00 per share, with underwriters granted a 30-day option for an additional 1,170,000 shares; the company did not sell shares or receive proceeds. Concurrently, the company repurchased 780,000 shares from the underwriters for approximately $16.5 million under its existing share repurchase program. The offering and repurchase were completed on March 23, 2026, pursuant to an effective S-3 shelf registration.

• ·Underwriting agreement includes customary representations, warranties, indemnification, and termination provisions.
• ·Offering made pursuant to effective Form S-3 (File No. 333-293202) declared effective February 10, 2026.

24-03-2026

Braemar Hotels & Resorts Inc. announced on March 24, 2026, that its Board of Directors declared March 2026 dividends on its 5.5% Series B Cumulative Convertible Preferred Stock, 8.25% Series D Cumulative Preferred Stock, Series E Redeemable Preferred Stock, and Series M Redeemable Preferred Stock. As of February 28, 2026, the Company had 11,528,242 shares of Series E Redeemable Preferred Stock and 1,382,407 shares of Series M Redeemable Preferred Stock issued and outstanding.

24-03-2026

The 10-K annual report for Benchmark 2020-B22 Mortgage Trust, filed March 24, 2026, assesses compliance with Regulation AB Rule 1122(d) servicing criteria by servicers including Midland and KeyBank. Most applicable criteria across general servicing, cash collection, investor remittances, and pool asset administration were performed directly or by responsible vendors, with no material non-compliance noted. However, numerous criteria are designated as N/A or not applicable due to the transaction structure, limiting the scope of assessment.

24-03-2026

NW Natural, a subsidiary of Northwest Natural Holding Company, filed a settlement (Stipulation) in its Washington rate case with the WUTC for annual revenue increases of $20.1M in Year 1 (starting Aug 1, 2026), $7.7M in Year 2, and $8.7M in Year 3, which is lower than originally requested ($25.6M, $8.6M, $8.3M) in Years 1 and 2 but slightly higher in Year 3. The settlement assumes a 9.5% ROE, 50/50 debt-equity capital structure, and growing average rate base from $328.0M in Year 1 (up $80.7M since last rate case) to $410.7M in Year 3, pending WUTC approval with new rates expected August 1, 2026. It resolves all issues except the line extension allowance policy.

• ·Previous Washington general rate case completed in 2021.
• ·Stipulation filed by NW Natural, WUTC Staff, The Energy Project, and Alliance of Western Energy Consumers (all but one party).
• ·Cost of long-term debt: 4.806% (Year 1), 4.863% (Year 2), 4.936% (Year 3).
• ·Overall rate of return: 7.15% (Year 1), 7.18% (Year 2), 7.22% (Year 3).
• ·Plant placed into service after March 31, 2025 subject to review, adjustment, and refund.
• ·Line extension allowance policy not addressed, subject to ongoing litigation.

24-03-2026

Smith-Midland Corporation announced preliminary unaudited Q4 2025 revenue of $22-24 million, a 25% increase from $18.5 million in Q4 2024, driven by higher product sales, shipping, and installation revenue. Full-year 2025 revenue is expected at $92-94 million, representing an 18% increase from 2024 at the midpoint, with anticipated record annual net income and higher Q4 net income versus prior year. Results reflect strong infrastructure demand and execution of growth strategies including rental barrier fleet expansion.

• ·Preliminary results for period ended December 31, 2025
• ·Form 10-K to be filed no later than March 31, 2026
• ·Manufacturing facilities: Midland, VA; Reidsville, NC; Columbia, SC

24-03-2026

Inflection Point Acquisition Corp. V, a SPAC, completed its IPO raising $86.25M in gross proceeds, funding a trust account of $89.3M at $10.36 per redeemable share, and reported net income of $397K for the year ended December 31, 2025, primarily from $3.1M interest income. However, it recorded a $2.7M operating loss from formation and operating costs, leading to a shareholders' deficit of $6.0M and only $26K cash outside the trust, with total assets growing to $89.5M from $0.13M prior period. Compared to the inception period through December 31, 2024, operating losses worsened significantly by approximately 35,200%, though offset by interest income.

• ·8,625,000 Class A ordinary shares subject to redemption at $10.36 per share.
• ·Deferred offering costs of $131,602 reclassified and paid in 2025.
• ·Net cash used in operating activities: $701K in 2025 vs provided $107K in prior period.
• ·IPO-related non-cash items include $13.3M remeasurement adjustment on redeemable shares and $7.8M allocated to public rights.

24-03-2026

On March 23, 2026, Ready Capital Corporation issued a notice of redemption for all outstanding 6.20% Senior Notes due 2026 (trading symbol RCB), to be redeemed on April 22, 2026, at 100% of the principal amount plus accrued and unpaid interest through the redemption date, funded by available cash. The redemption is pursuant to the Indenture dated August 9, 2017, as supplemented. No other performance metrics or comparisons were disclosed.

• ·Indenture details: Base Indenture dated August 9, 2017, supplemented by Third Supplemental Indenture dated February 26, 2019, and Fourth Supplemental Indenture dated July 22, 2019.
• ·Registrant details: Maryland incorporation, Commission File Number 001-35808, IRS EIN 90-0729143, principal offices at 1251 Avenue of the Americas, 50th Floor, New York, NY 10020.

24-03-2026

Appendix B of BANK5's 10-K filing details compliance assertions for servicing criteria under Regulation AB across multiple entities involved in asset-backed securities servicing. The company and servicers like Midland, CoreLogic, and KeyBank confirm performance of most criteria in general servicing considerations, cash collection, and pool asset administration either directly or via responsible vendors. However, numerous investor remittances and reporting criteria (e.g., 1122(d)(3)(i)(B)-(D), (ii)-(iv)) are marked as not performed, N/A, or inapplicable, particularly for certain platforms.

• ·Several criteria such as 1122(d)(1)(iii) (back-up servicer) and 1122(d)(4)(xv) (external enhancements) are explicitly not performed or N/A.
• ·Reconciliations for bank accounts must be prepared within 30 calendar days and reconciling items resolved within 90 calendar days.
• ·Funds held in escrow analyzed annually and returned within 30 calendar days of repayment.

24-03-2026

The 10-K annual report for Benchmark 2018-B7 Mortgage Trust, filed on March 24, 2026, contains compliance assertions under Regulation AB Item 1122 from servicers including KeyBank, PBLS1, and Green Loan Services LLC. These parties confirm adherence to most applicable servicing criteria for general servicing, cash collection, investor reporting, and pool asset administration, either directly or via responsible vendors, with certain criteria marked as N/A or not performed where inapplicable to their roles. No material instances of non-compliance or exceptions are disclosed.

24-03-2026

Aardvark Therapeutics, Inc. entered into an Equity Distribution Agreement with Piper Sandler & Co. on March 23, 2026, enabling the company to offer and sell shares of its common stock with an aggregate offering price of up to $150M through the agent. The agreement provides for a 3.0% commission to the agent on gross sales prices, with no obligation to sell any shares. This ATM facility supports potential future fundraising via the company's shelf registration on Form S-3 (No. 333-294537).

• ·Common stock par value: $0.00001 per share
• ·Trading symbol: AARD
• ·Agreement filed as Exhibit 10.1

24-03-2026

Suzano S.A.'s 20-F annual report filed on March 24, 2026, discloses board of directors (9 members elected April 25, 2024, terms to April 25, 2026), executive officers (6 members led by CEO João Alberto Fernandez de Abreu elected May 8, 2025, terms to post-2026 AGM), fiscal council, and audit committee composition. Compensation structure shows fixed pay dominating board remuneration at 49.4% with no variable pay, while executives have 35.1% in long-term incentives but lower fixed at 13.3%. As of December 31, 2024, total employees stood at 23,094, with major shareholder Suzano Holding S.A. holding 29.1% of common shares and public float at 48.5%.

• ·Fiscal Council has 3 members, all remunerated at R$0.36M average (2025).
• ·Board of Directors and executives hold 0.5% of common shares.
• ·Treasury shares represent 2.2% of total capital.

24-03-2026

Galaxy Group Investments LLC filed its 13F-HR on March 24, 2026, disclosing holdings as of December 31, 2024, with a portfolio concentrated in cryptocurrency ETFs and mining stocks. Major positions include iShares Bitcoin Trust at $3.63B (shares), ARK 21Shares Bitcoin ETF at $2.27B, CleanSpark Inc at $3.32B, and Cipher Mining Inc at $1.58B. Additional exposure via calls on iShares Bitcoin Trust ($1.06B), Invesco QQQ ($1.02B), and puts on MicroStrategy ($1.23B) and SPDR S&P 500 ETF ($302M).

• ·Filing period end date: December 31, 2024
• ·Filed as of date: March 24, 2026
• ·Filer address: 107 Grand Street, 8th Floor, New York, NY 10013
• ·CompoSecure Inc warrants expiration: December 27, 2022

24-03-2026

The 10-K annual report for JPMDB Commercial Mortgage Securities Trust 2019-COR6 assesses compliance with Regulation AB Item 1122 servicing criteria by Midland, CoreLogic, and other servicers. Applicable criteria were generally performed directly or via responsible vendors, with many others deemed N/A and no material non-compliance noted. The filing confirms adherence to transaction agreements across cash collection, investor reporting, and pool asset administration without highlighting any deficiencies.

• ·Filing date: March 24, 2026
• ·Multiple servicing criteria marked as N/A (e.g., back-up servicer requirements, investor remittances)
• ·Timeframes referenced include deposits/postings within 2 business days, reconciliations within 30 days, and resolution of reconciling items within 90 days

24-03-2026

Galaxy Digital Capital Management GP LLC filed a 13F-HR report disclosing 40 investment positions with a total market value of $173.8 million as of December 31, 2024. The portfolio includes long positions (SH) and put options across cryptocurrency-related firms like Coinbase Global, MicroStrategy, Riot Platforms, Cipher Mining, CleanSpark, Bitdeer Technologies, and TeraWulf, as well as technology and financial stocks such as NVIDIA, AMD, Alphabet, BlackRock, JPMorgan Chase, Mastercard, Meta Platforms, and Visa. No prior period data is provided for comparison.

• ·Report period end: December 31, 2024
• ·Filing date: March 24, 2026
• ·Business address: 300 Vesey Street, 13th Floor, New York, NY 10282
• ·Holdings include both shares (SH) and put options (Put) designated as OTR
• ·SEC file number: 028-26779

24-03-2026

The Estée Lauder Companies Inc. confirmed it is in discussions regarding a potential business combination with Puig, under which the two companies would merge their businesses. No final decision has been made and no agreement has been reached, with no assurances regarding any deal or its terms. The announcement was made via a press release issued on March 23, 2026.

• ·Filing date: March 24, 2026
• ·Date of earliest event reported: March 23, 2026
• ·Principal executive offices: 767 Fifth Avenue, New York, New York 10153

24-03-2026

The 10-K annual report for CF 2019-CF3 Mortgage Trust details compliance assertions by servicers Midland, K-Star, PBLS, KeyBank, and the Asserting Party with Regulation AB servicing criteria (Item 1122) for the reporting period. Midland and KeyBank affirm compliance with most criteria directly or via responsible vendors, while K-Star and PBLS mark numerous criteria as not performed by them or their subservicers, reflecting their limited roles. No material non-compliance or exceptions are explicitly reported.

• ·Filing date: March 24, 2026
• ·Compliance assessed throughout the reporting period (exact period not specified)
• ·Standard timeframes referenced: 2 business days for deposits/postings, 30 calendar days for reconciliations/escrow returns, 90 calendar days for reconciling items

24-03-2026

The 10-K annual report for Benchmark 2020-B16 Mortgage Trust, filed March 24, 2026, contains Regulation AB 1122(d) servicing criteria compliance assessments by multiple servicers including Midland, Special Servicer, PBLS, and KeyBank. Across sections, most applicable criteria are reported as performed directly by the servicer or by vendors for which they are responsible, while others are designated N/A or inapplicable with no disclosed non-compliance exceptions. No financial performance metrics, delinquencies, or servicer changes are detailed.